Epix appoints marketing VP

Article

MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in

MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in phase II clinical trials for peripheral vascular disease, coronary artery disease, and breast cancer (SCAN 1/14/98). Mayer joins Cambridge, MA-based Epix from a position as worldwide marketing manager at pharmaceutical firm Chiron Diagnostics. He has also been employed by Abbott Diagnostics.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.